- Diagnostics
- Thursday, 02 Apr 2020
Jolly Good and National Center for Cognitive Behavior Therapy and Research Enter Clinical Trial Collaboration for VR Therapeutics
Jolly Good Inc. (hereinafter "Jolly Good") and the National Center for Cognitive Behavior Therapy and Research (hereinafter "NCCBTR") announced that they have entered into a clinical trial collaboration agreement directed toward the development of digital health solutions. Under the agreement, Jolly Good will develop and commercialize CBT VR in Japan and certain other overseas markets for patients with depression. Before the collaboration accord, Jolly Good applied for its "VR Diagnostic treatment system" patent in Japan on February 26, 2020 (patent application numbers: 2020-030723).
In the trial, the two partners will provide CBT focusing on a positive-valence system using VR toward patients with moderate to higher depression. In addition, they will test the safeness and effectiveness of VR therapeutics. The hypothesis is that by exposing patients under virtual reality related to positive-valence, it will decrease the suppression of activity making the patient available to find positive-valence in real-life situations as well. This will improve the symptoms of depressions, especially anhedonia. This research will prevent severe depression and decrease the number of hospitalized patients. In other words, the partners want to promote the use of VR and AI technology for effective treatment of depression that does not rely on drugs.
About Depression
Depressive disorders led to a global total of over 50 million Years Lived with Disability (YLD) in 2015. Globally, depressive disorders are ranked as the single largest contributor to non-fatal health loss (WHO, 2017). Mental disorder is considered as one of the five major diseases in Japan. Among them, especially depression has a large percentage (1.27 million patients), and the annual economic cost of depression totals up to 3.09 trillion yen.
About Cognitive Behavioral Therapy (CBT)
The purpose of CBT is to relieve symptoms and prevent recurrence of depression in mood, physical responses, etc., caused by stress through strengthening patient self-control by applying theories and behavior modification techniques of cognitive behavioral science.
Related Industry Updates
NSL Analytical Services Acquired by May River Capital
Jan 15, 2020
CooperRiis Launches New Insurance Driven Intensive Clinical Program
Jul 09, 2020
Asia Pacific Companion Animal Diagnostics Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027| Fujifilm Corporation, Skyla Corporation, Virbac
Nov 30, 2020
Indian Patients to Get Face-to-face Consultations for Coronavirus-2019
Feb 25, 2020
UK scientists UK team tests coronavirus vaccine on mice
Feb 13, 2020
Quest Diagnostics Begins to Perform COVID-19 Antibody Testing
Apr 22, 2020
PSA Test Explained: What It Is, How It Works, and Why It Matters
Mar 27, 2026